External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience AMCP Nexus 2023
Roche and Genentech at

AMCP Nexus 2023

October 16 - October 19
Orlando, USA
amcpnexus.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Oct 18 / Roche and Genentech
Real-world evidence for risdiplam▼-treated adults with spinal muscular atrophy: a multicenter study
Interim results of a retrospective, non-interventional cohort study in patients with SMA aged ≥25 years were presented. Aggregated data were collected from patients with ≥12-month follow-up after the start of risdiplam▼ treatment.​ Interim results suggested improved or maintained function across multiple outcomes.​ The number of patients receiving rehabilitation therapy increased compared with the 12 months preceding risdiplam▼ treatment. This study will address a critical need for descriptive information about the diagnosis, treatment, management and outcomes for this population.​
Neuroscience Spinal Muscular Atrophy AMCP-NEXUS-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 18 / Roche and Genentech
Household Flu Transmission and Healthcare Resource Use among Patients Treated with Baloxavir▼ versus Oseltamivir for Influenza: An Outpatient Prospective Survey in the United States
This poster describes a prospective electronic survey that reports the incidence of household transmission and healthcare resource utilization in patients with influenza treated with baloxavir▼ vs oseltamivir.
Infectious Disease Influenza Virus Infection AMCP-NEXUS-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 17 / Roche and Genentech
Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy
This poster outlines several practical considerations for the administration of delandistrogene moxeparvovec gene therapy in patients with DMD, based on learnings from clinical trial experience from Study 101 (SRP-9001-101; NCT03375164), Study 102 (SRP-9001-102; NCT03769116), and the ongoing ENDEAVOR study (Study 103; SRP-9001-103; NCT04626674).
Neuroscience Duchenne Muscular Dystrophy AMCP-NEXUS-2023
09:00 AM
Duration 180mins Orlando, USA
Potential Medication Wastage and Impact on Cost Due to Switching Treatment Among Persons With MS on Oral or Self-Injectable DMTs
DT Okuda, A Patel, R Schuldt, I Abioye, and NG Bonine
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:00 PM
Duration 210mins Orlando, USA
Household Flu Transmission and Healthcare Resource Use among Patients Treated with Baloxavir▼ versus Oseltamivir for Influenza: An Outpatient Prospective Survey in the United States
Best J, Sadeghi M, Sun X, Seetasith A, Albensi L, Joshi S, Zervos M
Infectious Disease | Influenza Virus Infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 210mins Orlando, USA
Real-world evidence for risdiplam▼-treated adults with spinal muscular atrophy: a multicenter study
S Shapouri, S Candrilli, L Miles, A Simpson, CJ Guittar
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 210mins Orlando, USA
Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy
R Mendell, C Proud, C Zaidman, S Mason, E Darton, C Wandel, AP Murphy, E Mercuri, F Muntoni, C McDonald, Mariam Alboustani
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.